Addex is developing therapies aimed at improving the management of Parkinson’s disease

Addex is developing therapies aimed at improving the management of Parkinson’s disease, a neurodegenerative disorder characterized by tremors, rigidity, and bradykinesia (slowness of movement). The company’s most advanced program, dipraglurant, is a selective mGlu5 receptor antagonist that has shown promise in clinical trials as a treatment for levodopainduced dyskinesia, a common and debilitating side effect of Parkinson’s disease treatment. Addex is researching the role of mGlu receptors in the pathophysiology of migraine, a debilitating condition that affects a significant portion of the population. The company aims to develop novel treatments for migraine that can offer better efficacy and fewer side effects than existing medications.